Bronchiectasis Therapeutic Market Segmentation:
Disease Type Segment Analysis
The non-cystic fibrosis bronchiectasis subsegment is expected to hold the highest market share of 83% in the disease type segment within the forecast period in the bronchiectasis therapeutic market due to a higher prevalence, broader categorization, and the worldwide increase in average population age. According to a report by NLM in March 2024, non-cystic fibrosis bronchiectasis is prevalent globally, yet the incidence is mostly unreported due to inaccurate diagnosis coding, with ICD-9-CM and ICD-10-CM codes displaying low sensitivities of only 34% and specificities ranging from 69% to 81%, respectively. This indicates a greater need for effective diagnostic tools and treatments.
Product Type Segment Analysis
The antibiotics subsegment is expected to hold the highest market share in the product type segment within the forecast period in the bronchiectasis therapeutic market. The hospitalization-at-home model seems to further inflate this cost. As per a report by NLM in October 2024, outpatient hospital costs are mainly due to drug prescriptions, especially antibiotics, and constitute as much as 41% of the total spending. Such a significant clinical and economic reliance on antibiotics intensifies their reliance in the treatment options available and further fuels the development and funding of newer, advanced, and targeted antibiotic delivery methods, including inhaled formulations and combination therapies.
Route of Administration Segment Analysis
The oral subsegment is expected to hold the highest market share in the route of administration segment within the forecast period for the bronchiectasis therapeutic market. Oral treatments are the most favored in terms of compliance. They are easier to self-administer and have better patient adherence. For example, oral mucolytics and antibiotics serve as the cornerstone treatment for bronchiectasis. These medications extend the care of bronchiectasis patients to out-of-hospital settings, enabling effective treatment. Furthermore, such oral therapies help reduce the use of invasive treatments and hospitalizations.
Our in-depth analysis of the bronchiectasis therapeutic market includes the following segments:
|
Segment |
Subsegments |
|
Product Type |
|
|
Disease Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
Geography |
|
